Loading…
Loading…
Counterpoint Mutual Funds LLC purchased a new stake in shares of Schrodinger, Inc. (NASDAQ: SDGR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 40,894 shares of the company's stock, valued at approximately $1,270,000. Counterpoint Mutual Funds LLC owned about 0.06% of Schrodinger
NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced the publication of new research in Nature that reveals critical insights into the atomic-scale structure of lithium-ion battery (LIB) electrolytes. In a joint study with researchers from Columbia University and the New York Structural Biology Center, the team discovered new insights that challenge long-held assumptions of the fundamental chemistry of lithium-ion batteries, including multi-lithium ion complexes that may.
Schrodinger (NASDAQ: SDGR - Get Free Report) and Claritev (NYSE: CTEV - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends. Profitability This table compares Schrodinger and Claritev's net margins, return
Teladoc Health (NYSE: TDOC - Get Free Report) and Schrodinger (NASDAQ: SDGR - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Risk and Volatility Teladoc Health has a beta of
On October 09, 2026, Schrodinger Inc (SDGR) shares rose 3.4%, currently trading at $27.28. This price is within a 52-week range of $10.95 to $33.78, demonstrati
Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Schrödinger, Inc. has undergone significant changes, including pipeline cuts and a strategic pivot away from solo clinical development. Despite software growth deceleration and pipeline setbacks, SDGR's financials improved with the Ajax sale and a stronger balance sheet. SDGR's net income turned positive in Q2 2026, aided by a $48.9M gain from Ajax and increased cash reserves to $418.8M.
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company's common stock to three newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducem.